|
?:authorAffiliation
|
-
[\'Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA. jones_bryan_edward@lilly.com ester.falconer@abcellera.com.\', \'Eli Lilly and Company, Indianapolis, IN 46225, USA.\', \'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.\', \'AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.\', \'Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.\', \'University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.\', \'Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.\', \'Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, NY 10016, USA.\', \'Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.\', \'NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.\', \'Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.\', \'AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada. jones_bryan_edward@lilly.com ester.falconer@abcellera.com.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}